NCT05540626 is a NA clinical trial of Cala Trio in Essential Tremor, sponsored by Cala Health, Inc..

Who is sponsoring NCT05540626?

NCT05540626 is sponsored by Cala Health, Inc..

What drugs are being tested in NCT05540626?

Interventions in NCT05540626: Cala Trio.

What condition does NCT05540626 study?

NCT05540626 studies Essential Tremor.

Is NCT05540626 still recruiting?

NCT05540626 is currently completed. Last updated 7 May 2025.

Last reviewed 2025-05-07 · How we verify

NCT05540626

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RWE Study Utilizing the Cala Trio Device in Patients With Essential Tremor

Completed NA Last updated 7 May 2025

What this trial tests

NA trial testing Cala Trio in Essential Tremor in 276 participants. Completed in 1 March 2024.

Timeline

8 April 2021

Primary endpoint
1 March 2024

1 March 2024

Quick facts

Lead sponsor	Cala Health, Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	276
Start date	8 April 2021
Primary completion	1 March 2024
Estimated completion	1 March 2024
Sites	1 location across United States

Drugs / interventions tested

Cala Trio

Conditions studied

Essential Tremor — all drugs for Essential Tremor →

Sponsor

Cala Health, Inc. — full company profile →

Who can join

22 and older, any sex, with Essential Tremor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study objective is to evaluate hand tremor relief in the treated hand following stimulation with the Cala Trio Device in adults with essential tremor, and healthcare resource utilization and total healthcare costs over a 12-month period.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Comparative Effectiveness of Transcutaneous Afferent Patterned Stimulation Therapy for Essential Tremor: A Randomized Pragmatic Clinical Trial.
Dai D, Fernandes J, Kim H, Coetzer H. · · 2023 · cited 12× · PMID 37869579 · DOI 10.5334/tohm.798
Non-Invasive Transcutaneous Afferent Patterned Stimulation Therapy Offers Action Tremor Relief in Parkinson's Disease.
Brillman S, Khemani P, Isaacson SH, Pahwa R, et al · · 2023 · cited 3× · PMID 37637850 · DOI 10.5334/tohm.762
Poster Abstracts - Academy of Managed Care Pharmacy 2023
· 2023

Verify or expand the search:

Other recruiting trials for Essential Tremor

Currently open trials in the same condition.

NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
NCT07172295 — Modulate Tremor Severity With Low-intensity Focused Ultrasound Stimulation Targeting the Deep Nucleus of Patients With R · NA · recruiting
NCT07016425 — Temporal Interference for Essential Tremor · NA · recruiting
NCT07049003 — Deep Brain Stimulation of the Deep Cerebellar Nuclei for Refractory Tremor · Phase 1 · recruiting
NCT06428526 — Impact of Sensory Electrical Stimulation on Sensation and Tremor · NA · active not recruiting

Other Cala Health, Inc. trials

Trials by the same sponsor.

NCT05662059 — Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) Study in Ulcerative Colitis · NA · unknown
NCT05480215 — Symptomatic Relief of Action Tremor With Cala Trio Using Trio+ Bands · NA · completed
NCT05012579 — Transcutaneous Afferent Patterned Stimulation (TAPS) for Reduction of Parkinson's Disease (PD) Related Action Tremor · NA · completed
NCT03597100 — Prospective Study for Symptomatic Relief of ET With Cala Therapy · NA · completed
NCT03152136 — A Pilot Study of the Cala ONE Device for Essential Tremor · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05540626 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cala Health, Inc.
Last refreshed: 7 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05540626.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing